PE20070012A1 - Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil) ftalazin-1-ilo] micronizado, y sus sales - Google Patents

Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil) ftalazin-1-ilo] micronizado, y sus sales

Info

Publication number
PE20070012A1
PE20070012A1 PE2006000620A PE2006000620A PE20070012A1 PE 20070012 A1 PE20070012 A1 PE 20070012A1 PE 2006000620 A PE2006000620 A PE 2006000620A PE 2006000620 A PE2006000620 A PE 2006000620A PE 20070012 A1 PE20070012 A1 PE 20070012A1
Authority
PE
Peru
Prior art keywords
ilo
micronized
chlorophenyl
immediate release
drug load
Prior art date
Application number
PE2006000620A
Other languages
English (en)
Inventor
Kai Juergens
Thomas Backensfeld
Adrian Funke
Heiko Kranz
Kai Thode
Thorsten Wagner
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20070012A1 publication Critical patent/PE20070012A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA SOLIDA DE LIBERACION INMEDIATA Y CON UNA CARGA DE DROGA ELEVADA QUE COMPRENDE: A) AL MENOS 50% EN PESO DE LA FORMULACION TOTAL DEL PRINCIPIO ACTIVO (4-CLOROFENIL)[4-(4-PIRIDILMETIL)-FTALAZIN-1-ILO] MICRONIZADO, SIENDO PREFERIDA BAJO LA FORMA DE SAL SUCCINATO Y B) AL MENOS UN DESINTEGRANTE EN BASE A CARBOXIMETILCELULOSA TAL COMO CROSCARMELOSA SODICA EN UNA CANTIDAD DE 1-25% EN PESO DE LA FORMULACION. EN DONDE EL PRINCIPIO ACTIVO SE DISUELVE A PARTIR DE DICHA FORMULACION EN 30 MINUTOS Y TIENE UN VALOR d90 DE A LO SUMO 25um. TAMBIEN SE REFIERE A UNA PROCESO DE PREPARACION. ESTA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA PSORIASIS, RETINOPLASTIAS, ENFERMEDADES NEOPLASICAS
PE2006000620A 2005-06-07 2006-06-06 Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil) ftalazin-1-ilo] micronizado, y sus sales PE20070012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05090167A EP1731154A1 (en) 2005-06-07 2005-06-07 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)|4-(4-pyridylmethyl)pht halazin-1-yl| and salts thereof

Publications (1)

Publication Number Publication Date
PE20070012A1 true PE20070012A1 (es) 2007-02-07

Family

ID=34938468

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000620A PE20070012A1 (es) 2005-06-07 2006-06-06 Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil) ftalazin-1-ilo] micronizado, y sus sales

Country Status (22)

Country Link
EP (2) EP1731154A1 (es)
JP (1) JP2008542421A (es)
KR (1) KR20080017443A (es)
CN (1) CN101242841A (es)
AR (1) AR054377A1 (es)
AU (1) AU2006256853A1 (es)
BR (1) BRPI0611818A2 (es)
CA (1) CA2610977A1 (es)
CR (1) CR9577A (es)
CU (1) CU20070272A7 (es)
DO (1) DOP2006000128A (es)
EC (1) ECSP078037A (es)
GT (1) GT200600243A (es)
IL (1) IL187906A0 (es)
MX (1) MX2007015495A (es)
NO (1) NO20080066L (es)
PE (1) PE20070012A1 (es)
RU (1) RU2007147953A (es)
TW (1) TW200716114A (es)
UY (1) UY29585A1 (es)
WO (1) WO2006131394A1 (es)
ZA (1) ZA200800113B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958615A1 (en) * 2007-02-13 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Solid pharmaceutical formulations of a homogeneous dispersion of active principles having pH-dependent solubility
EP1958616A1 (en) * 2007-02-13 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical formulations of 1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine or salts thereof
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6482802B1 (en) 1998-05-11 2002-11-19 Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases

Also Published As

Publication number Publication date
JP2008542421A (ja) 2008-11-27
CN101242841A (zh) 2008-08-13
TW200716114A (en) 2007-05-01
MX2007015495A (es) 2008-02-22
CA2610977A1 (en) 2006-12-14
ECSP078037A (es) 2008-01-23
UY29585A1 (es) 2007-01-31
ZA200800113B (en) 2009-07-29
DOP2006000128A (es) 2006-12-15
CU20070272A7 (es) 2010-09-30
IL187906A0 (en) 2008-03-20
BRPI0611818A2 (pt) 2010-09-28
RU2007147953A (ru) 2009-07-20
KR20080017443A (ko) 2008-02-26
CR9577A (es) 2008-03-06
GT200600243A (es) 2007-07-16
WO2006131394A1 (en) 2006-12-14
EP1888073A1 (en) 2008-02-20
AU2006256853A1 (en) 2006-12-14
NO20080066L (no) 2008-03-06
AR054377A1 (es) 2007-06-20
EP1731154A1 (en) 2006-12-13

Similar Documents

Publication Publication Date Title
CL2017003445A1 (es) Formas solidas y formulaciones de compuestos de imidazopirazina.
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
PA8629501A1 (es) Tabletas dispersables que comprenden un derivado de acido benzoico
AR078846A1 (es) Composicion para el tratamiento de la enfermedad de alzheimer
NI200700064A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos.
PE20071037A1 (es) SALES Y FORMULACIONES DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
HN2011000699A (es) El compuesto (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico en forma libre o de sal y composiciones y composicion farmaceutica que lo contiene.
AR072755A2 (es) Comprimido de carga de droga alta del compuesto 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
PA8586501A1 (es) Tabletas dispersables que comprenden un derivado de acido benzoico
ECSP12011699A (es) Tableta
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
AR067328A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
AR076300A1 (es) Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
PE20151607A1 (es) Formulaciones de compuestos organicos
PE20070012A1 (es) Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil) ftalazin-1-ilo] micronizado, y sus sales
NI200700031A (es) Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas
PE20091900A1 (es) Una formulacion farmaceutica solida
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica

Legal Events

Date Code Title Description
FC Refusal